IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.
1 other identifier
observational
90
0 countries
N/A
Brief Summary
To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2023
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2020
CompletedFirst Posted
Study publicly available on registry
July 23, 2020
CompletedStudy Start
First participant enrolled
July 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2023
CompletedAugust 9, 2023
August 1, 2023
2 days
July 19, 2020
August 7, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
To decrease the immunity complications in ITP patients
Early detection of immunity complications in ITP patients
Baseline
To decrease case fatality rate
Early detection of immunity complication will decrease mortality rate
Baseline
Study Arms (3)
ITP
Patient newly diagnosied with ITP
Treated
Patients with ITP recived treatment
Control
Healthy people
Interventions
Drug given to some patients with autoimmune disease
Eligibility Criteria
To study initially enrolled 90 patients with ITP in Assiut hospital
You may qualify if:
- Patients with ITP (moderate and sever) different age group.
You may not qualify if:
- Patients with stroke and myocardial infarction,malignant tumors or pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (4)
Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835. doi: 10.1182/blood-2017-03-754119. Epub 2017 Apr 17.
PMID: 28416506BACKGROUNDKistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520. doi: 10.1016/j.hoc.2013.03.001.
PMID: 23714309BACKGROUNDChen Z, Qu W, Wang HQ, Xing LM, Wu YH, Liu ZY, Zhang Y, Liu H, Dong XF, Tao JL, Shao ZH. [Relationship of Peripheral Blood IL-37 Expression with T Lymphocytes Subsets and NK Cells in Patients with Primary Immune Thrombocytopenia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1201-1207. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.034. Chinese.
PMID: 31418380BACKGROUNDZhao Y, Ni X, Xu P, Liu Q, Sun T, Liu X, Ji X, Qiu J, Li J, Wang S, Han P, Peng J, Hou M, Li G. Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). Cytokine. 2020 Jan;125:154853. doi: 10.1016/j.cyto.2019.154853. Epub 2019 Sep 23.
PMID: 31557634BACKGROUND
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident physician
Study Record Dates
First Submitted
July 19, 2020
First Posted
July 23, 2020
Study Start
July 30, 2023
Primary Completion
August 1, 2023
Study Completion
September 1, 2023
Last Updated
August 9, 2023
Record last verified: 2023-08